Real-World study tests daily pill for diabetes control

NCT ID NCT05230615

Completed Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This completed study in Italy looked at how well once-daily oral semaglutide (Rybelsus) works for adults with type 2 diabetes in everyday medical practice. Researchers tracked changes in blood sugar and body weight over 8-10 months in 458 participants. The goal was to see if this pill helps lower blood sugar levels and manage weight in a real-world setting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: oral semaglutide (Rybelsus)
What this could lead to: If successful, this study could confirm that oral semaglutide is effective for managing blood sugar and weight in real-world type 2 diabetes patients.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by other factors. It also only includes Italian adults, so findings may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 2

Contacts and locations

Locations

IRCCS MultiMedica

Sesto San Giovanni, Italy
Master Centre for Italy

Rome, 00144, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.